Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

154.22 -1.44 (-0.93%)
Official Closing Price Updated: 7:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream
Via The Motley Fool
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Via The Motley Fool
NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision
NVIDIA (NASDAQ: NVDA) has introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
Exposures Political Tariff
P/E Ratio Insights for Johnson & Johnson
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
Exposures Product Safety
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
Exposures Political
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge. 
Via Benzinga
Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead
Josh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock. 
Via Benzinga
What's a Fair Price to Buy Johnson & Johnson Stock?
Via The Motley Fool
2 Stocks to Buy if There Is a Market Crash in 2025
Via The Motley Fool
Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates
Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ongoing efforts to refine its medtech division. 
Via Benzinga
Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself'
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
Kenvue's Q4 Sales Miss, Margins Improve
Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Johnson & Johnson's Options Frenzy: What You Need to Know
Via Benzinga
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
From Johnson & Johnson
Via Business Wire
Can Biotech Stocks Survive The Precarious Macro?
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Via The Motley Fool
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?
Via The Motley Fool
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.